APOC3 and coronary artery calcification: Genetic studies have also shown that carriers of the APOC3 null mutation R19X have 50% lower plasma apoC-III levels, 35% lower plasma triglycerides, markedly lower postprandial triglycerides and significantly lower coronary artery calcification (CAC) scores than non-carriers (96, 97).